Monotard

RSS

Withdrawn

This medicine's authorisation has been withdrawn

insulin human (rDNA)
MedicineHumanWithdrawn

Icelandic is available via eTranslation, the European Commission's machine translation service.

Translate to Icelandic | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 7 October 2002 the European Commission issued a marketing authorisation valid throughout the European Union for the medicinal product Monotard, insulin human, 40 IU/ml and 100 IU/ml, 10 ml vial, which have been approved for treatment of diabetes mellitus. 

The marketing authorisation holder (MAH) responsible for Monotard is NovoNordisk A/S. The European Commission was notified by the MAH of its decision through the MAH’s letter dated 25 September 2006 to voluntarily withdraw the marketing authorisation for Monotard for commercial reasons. Therapeutic alternatives are available throughout the European Union. 

On 14 November 2006 the European Commission issued a decision to withdraw the marketing authorisation for Monotard. 

Pursuant to this decision the European Public Assessment Report for Monotard is updated to reflect that the marketing authorisation is no longer valid.

español (ES) (273.86 KB - PDF)

Skoða

čeština (CS) (425.37 KB - PDF)

Skoða

dansk (DA) (273.79 KB - PDF)

Skoða

Deutsch (DE) (273.9 KB - PDF)

Skoða

eesti (ET) (272.92 KB - PDF)

Skoða

ελληνικά (EL) (455.13 KB - PDF)

Skoða

français (FR) (274.59 KB - PDF)

Skoða

italiano (IT) (273.59 KB - PDF)

Skoða

latviešu (LV) (440.65 KB - PDF)

Skoða

lietuvių (LT) (410.54 KB - PDF)

Skoða

magyar (HU) (427.29 KB - PDF)

Skoða

Nederlands (NL) (274.63 KB - PDF)

Skoða

polski (PL) (443.15 KB - PDF)

Skoða

português (PT) (273.88 KB - PDF)

Skoða

slovenčina (SK) (431.73 KB - PDF)

Skoða

slovenščina (SL) (423.48 KB - PDF)

Skoða

suomi (FI) (273.29 KB - PDF)

Skoða

svenska (SV) (273.29 KB - PDF)

Skoða

Product information

español (ES) (509.88 KB - PDF)

Skoða

dansk (DA) (518.7 KB - PDF)

Skoða

Deutsch (DE) (529.62 KB - PDF)

Skoða

ελληνικά (EL) (953.54 KB - PDF)

Skoða

français (FR) (530.38 KB - PDF)

Skoða

italiano (IT) (517.19 KB - PDF)

Skoða

Nederlands (NL) (518.82 KB - PDF)

Skoða

português (PT) (516.93 KB - PDF)

Skoða

suomi (FI) (509.34 KB - PDF)

Skoða

svenska (SV) (513.56 KB - PDF)

Skoða
Latest procedure affecting product information:C/0440
25/04/2002
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

español (ES) (273.56 KB - PDF)

Skoða

čeština (CS) (316.47 KB - PDF)

Skoða

dansk (DA) (275.34 KB - PDF)

Skoða

Deutsch (DE) (278.02 KB - PDF)

Skoða

eesti (ET) (272.64 KB - PDF)

Skoða

ελληνικά (EL) (319.35 KB - PDF)

Skoða

français (FR) (272.82 KB - PDF)

Skoða

italiano (IT) (272.57 KB - PDF)

Skoða

latviešu (LV) (316.75 KB - PDF)

Skoða

lietuvių (LT) (293.6 KB - PDF)

Skoða

magyar (HU) (317.06 KB - PDF)

Skoða

Nederlands (NL) (273.42 KB - PDF)

Skoða

polski (PL) (317.89 KB - PDF)

Skoða

português (PT) (274.51 KB - PDF)

Skoða

slovenčina (SK) (317.04 KB - PDF)

Skoða

slovenščina (SL) (303.5 KB - PDF)

Skoða

suomi (FI) (271.59 KB - PDF)

Skoða

svenska (SV) (273.7 KB - PDF)

Skoða

Product details

Name of medicine
Monotard
Active substance
insulin human
International non-proprietary name (INN) or common name
insulin human (rDNA)
Therapeutic area (MeSH)
Diabetes Mellitus
Anatomical therapeutic chemical (ATC) code
A10AC01

Pharmacotherapeutic group

Drugs used in diabetes

Therapeutic indication

Treatment of diabetes mellitus.

Authorisation details

EMA product number
EMEA/H/C/000440
Marketing authorisation holder
Novo Nordisk A/S

DK-2880 Bagsværd
Denmark

Marketing authorisation issued
07/10/2002
Withdrawal of marketing authorisation
14/11/2006

Assessment history

This page was last updated on

Share this page